PERCF (Percheron Therapeutics) Ending Cash Position: $2.96 Mil (As of Dec. 2025)


What is Percheron Therapeutics Ending Cash Position?

Percheron Therapeutics PERCF -0.18% Ending Cash Position is $2.96 Mil as of Dec. 2025. The stock has 2 warning signs investors should review.

Percheron Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was $2.96 Mil.

Percheron Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 ($11.01 Mil) to Jun. 2025 ($6.62 Mil) and declined from Jun. 2025 ($6.62 Mil) to Dec. 2025 ($2.96 Mil).

Percheron Therapeutics's annual Ending Cash Position increased from Jun. 2023 ($7.36 Mil) to Jun. 2024 ($7.88 Mil) but then declined from Jun. 2024 ($7.88 Mil) to Jun. 2025 ($6.62 Mil).

Percheron Therapeutics Ending Cash Position Related Terms

Percheron Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Percheron Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Percheron Therapeutics Ending Cash Position Chart

Percheron Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.60 13.52 7.36 7.88 6.62

Percheron Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.51 7.88 11.01 6.62 2.96

Percheron Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Percheron Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=7.726+-1.106
=6.62

Percheron Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.756+-3.795
=2.96

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $2.96 Mil mean?
Percheron Therapeutics (PERCF) has a Ending Cash Position of $2.96 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Percheron Therapeutics and its competitors.
Is Percheron Therapeutics' Ending Cash Position too high?
Percheron Therapeutics' current Ending Cash Position is $2.96 Mil.
How does Percheron Therapeutics' Ending Cash Position compare to ZTS and UTHR?
Percheron Therapeutics' Ending Cash Position of $2.96 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Percheron Therapeutics and its competitors. Percheron Therapeutics's current Ending Cash Position is $2.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Ending Cash Position of $2.96 Mil. The current Ending Cash Position is $2.96 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Ending Cash Position is $2.96 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Percheron Therapeutics Business Description

Other Exchanges AWY0:GermanyPER:Australia
Address 35 Collins Street, Level 30, Collins Place, Melbourne, VIC, AUS, 3000
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.